← Back to Search

CAR T-cell Therapy

CAR T Cell Therapy for Multiple Myeloma (QUINTESSENTIAL Trial)

Phase 2
Recruiting
Research Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to test how well BMS-986393 works and how safe it is for people with multiple myeloma that has come back or not responded to previous treatment.

Who is the study for?
This trial is for adults with multiple myeloma that has come back or hasn't responded to treatment. Specific details about who can join are not provided, but typically participants need to meet certain health standards and have a history of the condition being studied.
What is being tested?
The study is testing BMS-986393, which is a CAR T cell therapy targeting GPRC5D, a protein often found on myeloma cells. The goal is to see how effective and safe this therapy is in treating patients whose multiple myeloma has relapsed or resisted other treatments.
What are the potential side effects?
While specific side effects for BMS-986393 aren't listed here, common ones for CAR T cell therapies include flu-like symptoms, fatigue, fever, difficulty breathing, and changes in blood pressure. Some may experience more severe immune reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
BOR of complete response (CR) [including stringent complete response sCR]
BOR of partial response (PR) or better
Best overall response (BOR)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: BMS-986393Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyLead Sponsor
15 Previous Clinical Trials
2,017 Total Patients Enrolled
6 Trials studying Multiple Myeloma
748 Patients Enrolled for Multiple Myeloma
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,569 Previous Clinical Trials
3,384,222 Total Patients Enrolled
76 Trials studying Multiple Myeloma
28,954 Patients Enrolled for Multiple Myeloma
~100 spots leftby Oct 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top